Related Experiment Video

Updated: Aug 8, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K

Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials

Alberto J Lorenzatti1

  • 1DAMIC Medical Institute, Rusculleda Foundation for Research Cordoba, Argentina.

European Cardiology
|May 12, 2021
PubMed

Insights

Targeting inflammation, specifically the cytokine IL-1β, in atherosclerosis reduces cardiovascular events. This review highlights inflammation

Area of Science:

  • Vascular Biology and Inflammation
  • Cardiovascular Disease Pathophysiology

Background:

  • Atherosclerosis is a chronic inflammatory vascular disease characterized by cholesterol accumulation and immune cell infiltration.
  • Inflammation, driven by pro-inflammatory cytokines and chemokines, is central to plaque formation and atherosclerotic complications.

Purpose of the Study:

  • To review the role of inflammation in atherosclerosis.
  • To identify key inflammatory players in atherosclerotic plaque development.
  • To assess therapeutic strategies targeting inflammation for cardiovascular event prevention.

Main Methods:

  • Literature review focusing on the pathophysiology of atherosclerosis and inflammation.
  • Analysis of clinical trial data, particularly the CANTOS trial.
  • Discussion of emerging therapeutic approaches targeting inflammatory pathways.

Main Results:

  • The CANTOS trial demonstrated that targeting the pro-inflammatory cytokine IL-1β significantly reduces secondary cardiovascular events.
  • Evidence supports the critical role of specific inflammatory mediators in driving atherosclerotic progression.

Conclusions:

  • Targeting IL-1β inflammation is a validated strategy for reducing cardiovascular risk in atherosclerosis.
  • Further research into inflammatory pathways offers potential for novel atheroprotective therapies.

Keywords:
C-reactive proteinInflammationcanakinumabcardiovascularcolchicinecytokinesmethotrexate

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...